Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib in EGFR-mutated NSCLC
NCT03804580Phase 2Active, not recruiting
- Sponsor
- Vestre Viken Hospital Trust
- Start
- Dec 2018
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Vestre Viken Hospital Trust. Started Dec 2018; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03804580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03804580.